Price Controls Hurt Patients, Risk Future Innovation

Source: American Institute for Economic Research
by Courtney Quinn

“The U.S. Senate just announced legislation within Medicare Part D with the headline ‘lower prescription drug costs for beneficiaries living with cancer.’ Behind this headline, with a further examination of this proposal, there are caution lights and red flags raised by cancer survivors like myself and patient-focused healthcare organizations. The problem is the government price controls on medication within their proposal are filled with harmful provisions that will truly make it harder for cancer patients to afford their medications.” (08/02/22)